Luminate, an Ireland-based healthcare technology company developing home-based cancer care, has raised $21 million in an expanded Series A round. The funding brings total capital raised to over $50 million.
The round was co-led by Lachy Groom and ARTIS Ventures, with participation from Western Alliance Life Sciences, 8VC, Y Combinator, Atlantic Bridge, Faber, SciFounders, and Elkstone.
The funding follows the company’s $15 million Series A in September 2024, which was raised to expand beyond its Lily helmet for preventing chemotherapy-induced hair loss. This latest funding will support the launch of home cancer care at 40 partner oncology clinics in the United States through the company’s Lotus programme, which partners with oncologists and health insurers to move cancer drug infusions from hospital clinics to patients’ homes.
“Cancer doesn’t need to mean life-changing financial, time or physical burdens on patients,” said Aaron Hannon, CEO and co-founder of Luminate. “Luminate’s care model and technology can help providers stay in control of the patient’s treatment while scaling their impact to meet the growing future demand for cancer care. Importantly, we’re doing that while reducing the cost of care to the healthcare system, but most significantly, to the patient.”
Clinical studies for the Lotus auto-injector and remote monitoring technologies, designed to enable patient-led self-administration, are expected to begin in the first half of 2026, with a planned launch in mid-2026 subject to regulatory progress.
The company continues to develop Lily alongside Lilac, a device targeting peripheral neuropathy. Both are in clinical trials in the U.S. and Europe with market launch expected in 2027. Recruitment for the Lilac trial at St James’ Hospital in Dublin is set to begin in the coming weeks.
Luminate was founded in 2018 by Hannon, Dr. Barbara Oliveira, and Professor Martin O’Halloran at the University of Galway.
